Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …

Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …

Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Background About 20% of advanced non–small-cell lung cancer (NSCLC) cases harbor
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …

Background Resistance to first-generation or second-generation EGFR tyrosine kinase
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small …

Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …

Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …

Background Recent study showed that the combination of erlotinib and bevacizumab had
better disease control than erlotinib monotherapy in patients with advanced epidermal …

Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …